Matthew Lanchantin
Matt Lanchantin is the Head of Corporate Development at Syntis Bio, a biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare metabolic diseases. He oversees capital sourcing, strategic partnerships, and portfolio development, with a focus on identifying and advancing novel therapeutic and/or drug delivery applications for the company’s SYNT™ technology platform. Matt is also a co-founder of Nucleate, a global nonprofit dedicated to empowering the next generation of biotech leaders and entrepreneurs. He began his career at the bench and has since held research and strategy roles across multiple life sciences companies, leading licensing and M&A transactions spanning oncology, cardiovascular, and metabolic diseases. Matt holds an MBA from the MIT Sloan School of Management and a BS in Chemical and Biological Engineering from Tufts University.
Syntis Bio
Reprogramming Drug Delivery: How Synthetic Biology is Unlocking the Next Generation of Therapeutics
-
Synthetic biology is redefining drug delivery, enabling breakthroughs in precision, targeting, and bioavailability. But what does synthetic biology really mean in this space? This panel brings together a diverse group of entrepreneurs and pharmaceutical leaders to discuss how they integrate synthetic biology to overcome key delivery challenges. Panelists will also explore the strategic questions of building a drug delivery company: Should they develop their own therapeutics or partner with pharma? How do they avoid commoditization and create lasting value? Join us for a dynamic discussion at the intersection of science and strategy in next-generation drug delivery.
Conference Pass
2,495
USD
Keynotes & Firesides
Workshops & Breakouts
1:1 Partnering App
Meals & Receptions
Session Recordings
Until Friday April 18th
Full Rate:
$3,495
